Published 1 day ago • loading... • Updated 1 day ago

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

At the American Association for Cancer Research Annual Meeting in San Diego, which concluded Wednesday, Abbisko Therapeutics presented six preclinical and translational research findings spanning multiple cancer inhibitors.
Abbisko highlighted ABSK211 and ABK-EGFR-1 to address clinical resistance in KRAS and EGFR-mutant cancers, with ABK-EGFR-1 targeting the EGFR C797S mutation affecting an estimated 51,000 to 146,000 patients annually.
Preclinical data for ABK-CDK4 demonstrated over 50-fold selectivity versus CDK6, potentially reducing toxicity for patients with brain metastases, while ABSK131 showed synergistic activity in MTAP-deleted solid tumors.
Abbisko also shared results from a ctDNA-based study analyzing resistance mechanisms to the FGFR2/3 inhibitor ABSK061, providing molecular insights to inform future sequential treatment strategies.
As these programs advance, Abbisko aims to deliver first-in-class therapies to patients worldwide, with ABSK211 currently undergoing IND-enabling studies to support its clinical development.

Insights by Ground AI

24 Articles

The Union Democrat

+23 Reposted by 23 other sources

Center

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17…

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year